Avoid Prescription Drugs: Electrocute Yourself With Electroceuticals Instead

With all the controversy of Zohydro (a powerful drug for chronic pain that is about to be launched into the market, with FDA approval despite an 11-2 vote against it by independent experts), the field of electroceuticals has been launched back into the news.

Nervous SystemNervous System

20 years ago researchers discovered that stimulating the vagus nerve puts brakes on the immune system - the source of pain and inflammation, and invented the field of bioelectronics to develop alternatives to drugs to manipulate the nervous system. "Electroceuticals" are the result.

A big player in the field of electroceuticals is GlaxoSmithKlein who are pumping money in the area. They reckon that bioelectrical medicines "could potentially coax insulin from cells to treat diabetes, regulate food intake to treat obesity and correct balances in smooth muscle tone to treat hypertension and pulmonary disease". 

But using electricity to treat pain and other conditions is not new. Defibrillators and pacemakers are both alternatives to drugs that use electrical stimulation to treat irregular heartbeats. Other examples are deep brain stimulation for Parkinson's disease, or Cochlear Implants which directly stimulate the auditory nervous system. 

Another example of electroceuticals is ActiPatch, a battery powered "band aid" that goes directly on the skin at the source of the pain, to reduce inflammation after facial surgery, or chronic pain in the knees, hips, shoulders or back. It works by sending pulses of electromagnetic energy to the target area, and has been found to give superior results to heat wraps or various NSAIDS.

Actipatch battery powered electromagnetic medical deviceActipatch battery powered electromagnetic medical device

It's clear that we need to make a step away from pharmaceuticals in many of the big diseases that are threatening our lifespans, and if we can manipulate our nervous systems with simple electronic pulses, it's worth investigating further.

Source: Wired